A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney Disease who are receiving a standardized dose of angiotensin converting enzyme inhibitor therapy
Latest Information Update: 31 Jul 2020
At a glance
- Drugs Valsartan (Primary)
- Indications Proteinuria; Renal failure
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 31 Jul 2020 New trial record